Published: 2 March 2021
Authors: Roham T. Zamanian, David Badesch, Lorinda Chung, Robyn T. Domsic, Thomas Medsger, Ashley Pinckney, Lynette Keyes-Elstein, Carla D’Aveta, Meagan Spychala, R. James White, Paul M. Hassoun, Fernando Torres, Andrew J. Sweatt, Jerry A. Molitor, Dinesh Khanna, Holden Maecker, Beverly Welch, Ellen Goldmuntz, and Mark R. Nicolls; on behalf of the NIH ASC01 Study Group
Source: This abstract has been sourced from NZ Respiratory Research Review Issue 190
Rationale: Systemic sclerosis (SSc)–pulmonary arterial hypertension (PAH) is one of the most prevalent and deadly forms of PAH. B cells may contribute to SSc pathogenesis.
Objectives: We investigated the safety and efficacy of B-cell depletion for SSc-PAH.
Methods: In an NIH-sponsored, multicenter, double-blinded, randomized, placebo-controlled, proof-of-concept trial, 57 patients with SSc-PAH on stable-dose standard medical therapy received two infusions of 1,000 mg rituximab or placebo administered 2 weeks apart. The primary outcome measure was the change in 6-minute-walk distance (6MWD) at 24 weeks. Secondary endpoints included safety and invasive hemodynamics. We applied a machine learning approach to predict drug responsiveness.
Measurements and Main Results: We randomized 57 subjects from 2010 to 2018. In the primary analysis, using data through Week 24, the adjusted mean change in 6MWD at 24 weeks favored the treatment arm but did not reach statistical significance (23.6 ± 11.1 m vs. 0.5 ± 9.7 m; P = 0.12). Although a negative study, when data through Week 48 were also considered, the estimated change in 6MWD at Week 24 was 25.5 ± 8.8 m for rituximab and 0.4 ± 7.4 m for placebo (P = 0.03). Rituximab treatment appeared to be safe and well tolerated. Low levels of RF (rheumatoid factor), IL-12, and IL-17 were sensitive and specific as favorable predictors of a rituximab response as measured by an improved 6MWD (receiver operating characteristic area under the curve, 0.88–0.95).
Conclusions: B-cell depletion therapy is a potentially effective and safe adjuvant treatment for SSc-PAH. Future studies in these patients can confirm whether the identified biomarkers predict rituximab responsiveness.
Clinical trial registered with www.clinicaltrails.gov (NCT 01086540).
Link to abstract
NZ Respiratory Research Review Issue 190